Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

40.81 +0.71 (+1.77%)
Official Closing Price Updated: 7:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,825,441
Open 40.14
Bid (Size) 40.65 (81)
Ask (Size) 40.81 (1)
Prev. Close 40.10
Today's Range 39.94 - 40.86
52wk Range 39.23 - 56.32
Shares Outstanding 5,606,688,356
Dividend Yield 3.82%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Insiders Selling Pfizer And 2 Other Stocks
The Nasdaq Composite traded slightly higher on Monday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats 
Via News Direct
Topics Death Economy
Exposures COVID-19 Death Economy

Performance

YTD
-20.39%
-20.39%
1 Month
-4.43%
-4.43%
3 Month
-20.54%
-20.54%
6 Month
-10.19%
-10.19%
1 Year
-24.69%
-24.69%

More News

Read More
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
Via TheNewswire.com
Topics Death Economy
Exposures COVID-19 Death Economy
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
Via Benzinga
FDA Advisory Committee Votes Favoring Pfizer's COVID-19 Pill Paxlovid
Via Benzinga
Springing into Your Health
Via Brandpoint
Pfizer Unusual Options Activity For March 16
Via Benzinga
Pfizer Unusual Options Activity For March 15
Via Benzinga
2 Undervalued Stocks to Buy Today to Prepare for the Next Bull Market
Via The Motley Fool
1 Top Healthcare Stock That Could Make You Richer in the Next Decade
Via The Motley Fool
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
Via Talk Markets
MarketBeat Week in Review – 3/13 - 3/17
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
Via Investor's Business Daily
Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug
Via Benzinga
SVB Financial Officially Files For Bankruptcy, Yellen, Powell & Dimon Behind First Republic Bank's $30B Lifeline, Playboy's $5M Loss On Ethereum: Today's Top Stories
Via Benzinga
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?
Via The Motley Fool
Pfizer Working To Develop New Packaging For Migraine Drug Over Child Safety, Poisoning Concerns
Via Benzinga
7 High-Yield Dividend Stocks That Can Double Your Money in 2023
Via InvestorPlace
7 Stocks Set to Soar When the Market Recovers
Via InvestorPlace
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
From Pfizer Inc.
Via Business Wire
Stifel Is Bullish On This 'Competitive Late-Comer' In Gastric Cancer Space
Via Benzinga
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
Via Investor's Business Daily
This Must-Buy Dividend Growth Stock Could Pay You for Life
Via The Motley Fool
Here's Why Pfizer Stock Is Looking Increasingly Attractive
Via The Motley Fool
Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.